These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

788 related items for PubMed ID: 27086918

  • 1. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.
    Chowdhury S, Veyhl J, Jessa F, Polyakova O, Alenzi A, MacMillan C, Ralhan R, Walfish PG.
    Oncotarget; 2016 May 31; 7(22):32318-28. PubMed ID: 27086918
    [Abstract] [Full Text] [Related]

  • 2. Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and Recurrence.
    Shi RL, Qu N, Luo TX, Xiang J, Liao T, Sun GH, Wang Y, Wang YL, Huang CP, Ji QH.
    Thyroid; 2017 Apr 31; 27(4):537-545. PubMed ID: 27825291
    [Abstract] [Full Text] [Related]

  • 3. Independent prognostic role of PD-L1expression in patients with esophageal squamous cell carcinoma.
    Jiang D, Song Q, Wang H, Huang J, Wang H, Hou J, Li X, Xu Y, Sujie A, Zeng H, Tan L, Hou Y.
    Oncotarget; 2017 Jan 31; 8(5):8315-8329. PubMed ID: 28039448
    [Abstract] [Full Text] [Related]

  • 4. Programmed Death - Ligand 1 Expression Distinguishes Invasive Encapsulated Follicular Variant of Papillary Thyroid Carcinoma from Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features.
    Fu G, Polyakova O, MacMillan C, Ralhan R, Walfish PG.
    EBioMedicine; 2017 Apr 31; 18():50-55. PubMed ID: 28363612
    [Abstract] [Full Text] [Related]

  • 5. Programmed Death-Ligand 1 (PD-L1) Is a Potential Biomarker of Disease-Free Survival in Papillary Thyroid Carcinoma: a Systematic Review and Meta-Analysis of PD-L1 Immunoexpression in Follicular Epithelial Derived Thyroid Carcinoma.
    Girolami I, Pantanowitz L, Mete O, Brunelli M, Marletta S, Colato C, Trimboli P, Crescenzi A, Bongiovanni M, Barbareschi M, Eccher A.
    Endocr Pathol; 2020 Sep 31; 31(3):291-300. PubMed ID: 32468210
    [Abstract] [Full Text] [Related]

  • 6. PD-L1 and thyroid cytology: A possible diagnostic and prognostic marker.
    Dell'Aquila M, Granitto A, Martini M, Capodimonti S, Cocomazzi A, Musarra T, Fiorentino V, Pontecorvi A, Lombardi CP, Fadda G, Pantanowitz L, Larocca LM, Rossi ED.
    Cancer Cytopathol; 2020 Mar 31; 128(3):177-189. PubMed ID: 31821747
    [Abstract] [Full Text] [Related]

  • 7. Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Non-Small Cell Lung Cancer.
    Sepesi B, Cuentas EP, Canales JR, Behrens C, Correa AM, Vaporciyan A, Weissferdt A, Kalhor N, Moran C, Swisher S, Wistuba I.
    Semin Thorac Cardiovasc Surg; 2020 Mar 31; 29(3):408-415. PubMed ID: 29195578
    [Abstract] [Full Text] [Related]

  • 8. Association Between Programmed Death-Ligand 1 Expression and Clinicopathological Characteristics, Structural Recurrence, and Biochemical Recurrence/Persistent Disease in Medullary Thyroid Carcinoma.
    Shi X, Yu PC, Lei BW, Li CW, Zhang Y, Tan LC, Shi RL, Wang J, Ma B, Xu WB, Wang X, Hu JQ, Huang NS, Wei WJ, Wang Y, Chen TZ, Wang YL, Ji QH.
    Thyroid; 2019 Sep 31; 29(9):1269-1278. PubMed ID: 31328653
    [Abstract] [Full Text] [Related]

  • 9. Overexpression of G Protein-Coupled Receptor Kinase 6 (GRK6) Is Associated with Progression and Poor Prognosis of Papillary Thyroid Carcinoma.
    Che X, Zhang G, Zhang X, Xue J.
    Med Sci Monit; 2018 May 28; 24():3540-3548. PubMed ID: 29805156
    [Abstract] [Full Text] [Related]

  • 10. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
    Rashed HE, Abdelrahman AE, Abdelgawad M, Balata S, Shabrawy ME.
    Turk Patoloji Derg; 2017 May 28; 1(1):211-222. PubMed ID: 28832075
    [Abstract] [Full Text] [Related]

  • 11. Papillary thyroid carcinoma patients assessed to be at low or intermediary risk after primary treatment are at greater risk of long term recurrence if they are thyroglobulin antibody positive or do not have distinctly low thyroglobulin at initial assessment.
    Soyluk O, Boztepe H, Aral F, Alagol F, Özbey NC.
    Thyroid; 2011 Dec 28; 21(12):1301-8. PubMed ID: 22136265
    [Abstract] [Full Text] [Related]

  • 12. PD-L1 and B7-H3 are Effective Prognostic Factors and Potential Therapeutic Targets for High-Risk Thyroid Cancer.
    Zhu X, Hu C, Zhang Z, Zhu Y, Liu W, Zheng B, Feng X, Lu H.
    Endocr Pathol; 2024 Sep 28; 35(3):230-244. PubMed ID: 39102163
    [Abstract] [Full Text] [Related]

  • 13. Disparity expression of gammaH2AX in papillary thyroid cancer and nodular goiter.
    Hu S, Zhang G, Xu J, Zhu X, Lu X, Jiang L, Wang Q, Hou X, Cao J, Ge M.
    Clin Lab; 2014 Sep 28; 60(12):2031-7. PubMed ID: 25651738
    [Abstract] [Full Text] [Related]

  • 14. Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors.
    Zhang L, Qiu M, Jin Y, Ji J, Li B, Wang X, Yan S, Xu R, Yang D.
    Int J Clin Exp Pathol; 2015 Sep 28; 8(9):11084-91. PubMed ID: 26617827
    [Abstract] [Full Text] [Related]

  • 15. Papillary Thyroid Carcinoma Emerging from Hashimoto Thyroiditis Demonstrates Increased PD-L1 Expression, Which Persists with Metastasis.
    Lubin D, Baraban E, Lisby A, Jalali-Farahani S, Zhang P, Livolsi V.
    Endocr Pathol; 2018 Dec 28; 29(4):317-323. PubMed ID: 30121940
    [Abstract] [Full Text] [Related]

  • 16. Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma.
    Chen K, Cheng G, Zhang F, Zhang N, Li D, Jin J, Wu J, Ying L, Mao W, Su D.
    Oncotarget; 2016 May 24; 7(21):30772-80. PubMed ID: 27120796
    [Abstract] [Full Text] [Related]

  • 17. PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28-8 and E1L3N).
    Ma J, Li J, Qian M, Han W, Tian M, Li Z, Wang Z, He S, Wu K.
    Diagn Pathol; 2018 Nov 21; 13(1):91. PubMed ID: 30463584
    [Abstract] [Full Text] [Related]

  • 18. Projecting Survival in Papillary Thyroid Cancer: A Comparison of the Seventh and Eighth Editions of the American Joint Commission on Cancer/Union for International Cancer Control Staging Systems in Two Contemporary National Patient Cohorts.
    Pontius LN, Oyekunle TO, Thomas SM, Stang MT, Scheri RP, Roman SA, Sosa JA.
    Thyroid; 2017 Nov 21; 27(11):1408-1416. PubMed ID: 28891405
    [Abstract] [Full Text] [Related]

  • 19. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.
    Loh KC, Greenspan FS, Gee L, Miller TR, Yeo PP.
    J Clin Endocrinol Metab; 1997 Nov 21; 82(11):3553-62. PubMed ID: 9360506
    [Abstract] [Full Text] [Related]

  • 20. PROGRAMMED CELL DEATH-LIGAND 1 OVEREXPRESSION IN THYROID CANCER.
    Zhang GQ, Wei WJ, Song HJ, Sun ZK, Shen CT, Zhang XY, Chen XY, Qiu ZL, Luo QY.
    Endocr Pract; 2019 Mar 21; 25(3):279-286. PubMed ID: 30913016
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.